NOW Foods Berberine Glucose Support is the right pick if you want a one-bottle solution with real-dose adjuncts and don't mind locking yourself into a combo formula. At $20/month for 90 softgels combining 400 mg berberine HCl + 200 mg alpha-lipoic acid + 100 mg cinnamon per serving, it's the exception to the 'avoid combo formulas' rule because the adjunct dosing is genuine — ALA at the lower trial range (200 mg), not sprinkle. NOW's 30-year QC pedigree (NSF-registered facility, in-house testing labs, no major recalls) backs the brand-level safety. The trade-off is you can't titrate berberine independently. Six weeks at 2 softgels/day, here's the breakdown.
Check on AmazonAffiliate link — Super Achiever Club earns a small commission at no extra cost to you.
Read the complete Berberine guide →Standard berberine HCl in softgel matrix — same ~1% oral bioavailability as other HCl bottles, but the softgel oil emulsification may marginally improve absorption versus dry caps. The combo with alpha-lipoic acid is mechanistically additive (different glucose-lowering pathways: AMPK + PI3K/Akt), which is a real form-level benefit even though it doesn't change berberine's bioavailability per se. Loses 1.5 to phytosome (#5), holds even with other HCl bottles.
400 mg berberine per 2-softgel serving = 800 mg/day at the standard 2-serving protocol. To hit Yin 2008's 1,500 mg/day clinical anchor, you'd need 4 softgels = 1,600 mg berberine PLUS 800 mg ALA + 400 mg cinnamon — at which point you're overshooting the adjuncts. Structurally, the combo locks you out of clean clinical-dose titration. The 800 mg/day default sits below the trial anchor but inside Lan 2015's broader effective dose range (1,000-1,500 mg/day was the trial window; 800 mg has documented partial response).
NOW Foods runs in-house labs at NSF-registered facilities with GMP compliance and a 30-year zero-major-recall track record. The in-house QC standard is among the most consistent in the industry — multiple consumer-lab independent tests (ConsumerLab.com, LabDoor) have confirmed NOW products to be label-accurate at high reliability. Not NSF Certified (that's per-batch external testing), but the brand-level QC is structurally above the GMP-baseline tier.
$20 per 90-softgel bottle = $0.22/softgel. At 2 softgels/day for the 800 mg berberine + 400 mg ALA + 200 mg cinnamon protocol = $13.50/month. Strong value when you account for the bundled adjuncts — buying ALA separately at 200 mg/day is ~$10/month, so the combo effectively delivers berberine at ~$3.50/month implicit cost. The structural caveat is that the bundling locks you out of independent titration.
Verified-purchaser data on the combo formula shows consistent partial-to-full glucose response at the 2-softgel default protocol — most users see CGM glucose blunting and lipid improvements at week 8-12, with the ALA adjunct adding modest insulin-sensitivity uplift. The 30-year NOW brand pedigree means real-world outcomes have been observed across hundreds of thousands of users with consistent QC, which is structurally meaningful for a category where label-fraud is real.
“400 mg berberine HCl per serving + 200 mg alpha-lipoic acid + 100 mg cinnamon.”
Label-claim doses verified via NOW's batch testing and independent consumer-lab verification (ConsumerLab.com, LabDoor). Supplement facts panel transparently lists all three actives at their stated doses. Honest labeling — no proprietary blend masking.
“Supports healthy glucose metabolism already within the normal range.”
All three actives have published glucose-related trial data: berberine (Yin 2008, Lan 2015), ALA (Singh 2008, Mijnhout 2012 meta), cinnamon (Allen 2013 meta — modest effect at 1-3 g/day, smaller signal at the 100 mg dose). Effect sizes reproduce at NOW's combo doses with some attenuation on cinnamon's contribution due to under-dosing.
“GMP quality assured — manufactured in NOW's NSF-registered facility.”
NOW's Illinois facility is NSF-registered and GMP-compliant per 21 CFR Part 111. NOW also runs in-house QC labs at the facility for batch identity/purity testing. Verifiable via FDA inspection database and NSF facility registry. Real, audited, structurally above the GMP-baseline tier.
“Non-GMO and tested for purity.”
Both claims listed on NOW's allergen and source disclosure documents. The non-GMO claim is NOW-attested rather than third-party-certified, but the alkaloid sources don't come from GMO crops. In-house purity testing happens at the NSF-registered facility per batch.
“Comprehensive glucose-support formula.”
Marketing framing — accurate in spirit (the combo does address glucose support through complementary mechanisms), but oversold in claim. 'Comprehensive' implies trial-validated combination protocols, which the specific NOW combo doesn't have head-to-head versus monotherapy. The actives are individually trial-tested at their doses; the combo as a unit isn't separately validated.
The standard problem with 'berberine + metabolic adjuncts' formulas is that the adjuncts sit at sub-trial doses to fit the cap budget. NOW's combo is the exception: 200 mg alpha-lipoic acid per serving is the lower trial range from Singh 2008 (which used 300-600 mg/day for glycemic + neuropathy outcomes). At 2 servings/day you're getting 400 mg ALA — comfortably inside the trial window. ALA's mechanism (PI3K/Akt insulin-mimetic) is complementary to berberine's AMPK pathway, so the two are additive rather than redundant. This is one of the few combo formulas where the adjunct dosing pulls weight rather than just decorating the label.
At 2 softgels/day, you're getting 800 mg berberine — below the 1,500 mg Yin 2008 trial anchor but inside the broader effective range of 1,000-1,500 mg/day in Lan 2015's meta. Most users will see partial response (~70% of maximum effect size) at this dose. To hit full clinical dose, you'd need 4 softgels/day = 1,600 mg berberine PLUS 800 mg ALA + 400 mg cinnamon — at which point the ALA dose overshoots Singh 2008's upper trial range and you may get over-supplementation effects. The combo locks you into a specific dose ratio that doesn't fully cover Yin 2008's berberine protocol.
Cinnamon's glucose literature uses 1-3 g/day (Allen 2013 meta showed modest 0.1-0.3% HbA1c reduction in trials at that dose range). NOW's combo includes 100 mg cinnamon per serving = 200 mg/day at the standard protocol — well below trial-active doses. The cinnamon is real (Cinnamomum cassia extract, not flavor compound), but its measurable contribution to the formula's effect is minimal. Honest framing: the cinnamon is brand-positioning ('comprehensive glucose support') more than mechanistic contribution. The berberine and ALA do the actual work.
The softgel format genuinely helps some users with HCl tolerance — the gel shell dissolves more gradually than hard caps, smoothing peak luminal concentration. This is a meaningful tolerability advantage for users who got loose stools on hard-cap HCl bottles. The trade-off is softgel size: NOW's bottle ships large softgels (the combination of berberine + ALA + cinnamon + oil carrier doesn't compact small), which some users find harder to swallow than the equivalent two smaller hard caps. Choose softgel format intentionally for the GI advantage, not by accident.
A real adherence trap: users who are already taking standalone alpha-lipoic acid at 600 mg/day add NOW's berberine combo for 'better glucose support' without realizing they're now stacking 1,000+ mg ALA. ALA is generally safe across the trial range but can cause hypoglycemia at very high cumulative doses, especially in users also on glucose-lowering medications. Audit your full stack before adding combo formulas: if you're taking ALA separately, drop to 200-400 mg standalone or drop the combo and run single-ingredient berberine instead.
NOW Foods Berberine Glucose Support is the right pick if you want a one-bottle solution combining berberine with meaningful adjuncts (alpha-lipoic acid and cinnamon) and don't mind locking yourself into the combo's fixed dose ratios. The genuine differentiator is that NOW's ALA dose is real-dose (200 mg/serving = 400 mg/day at the standard protocol), sitting comfortably inside Singh 2008's diabetes-trial range. Combined with the 30-year NOW QC pedigree (NSF-registered facility, in-house testing labs, zero major recalls), the combo formula earns its place on this list as the honest mid-tier all-in-one pick. The structural caveats are real. The 2-softgel default delivers 800 mg berberine/day — below the Yin 2008 1,500 mg clinical anchor, though inside Lan 2015's broader effective range. Hitting full clinical dose requires 4 softgels/day, which overshoots the ALA dose. So NOW's combo works best for users who specifically want the combined adjunct stack (metabolic-syndrome carriers, diabetic-neuropathy sufferers, users already running ALA as part of their protocol). For users who want pure berberine at clinical dose with independent titration, jump to single-ingredient HCl picks (Thorne #1, Nutricost #2, Toniiq #3). Run 2 softgels/day with main meals for 12 weeks to evaluate response. If you respond at the lower 800 mg berberine dose, stay; if not, consider running NOW alongside a separate single-ingredient HCl bottle to top up berberine without overshooting the adjuncts.
Check NOW Foods · Berberine HCl + ALA + Cinnamon · 90 softgels on AmazonNSF Certified pure berberine HCl at the Yin 2008 trial dose — the right pick if you want full clinical-dose berberine with independent titration and don't need the adjunct stack.
See it on the list →Same berberine molecule at $15/month without the adjunct bundle — the right pick if you want pure berberine on a tight budget and prefer to buy ALA / cinnamon separately at independent doses.
See it on the list →Clinician-channel combo with berberine + milk thistle + ALA at trial-relevant doses — the right pick if you're working with a functional-medicine practitioner who specifically prescribes this brand.
See it on the list →Berberine 500 mg 3×/day (HCl form) for 3 months matched metformin 1,500 mg/day on HbA1c, fasting glucose, and postprandial glucose. NOW's default 800 mg/day (2 softgels) sits below this trial anchor; full clinical-dose protocols would require 4 softgels and overshoot the adjunct doses.
Comprehensive review confirming alpha-lipoic acid 300-600 mg/day improves glycemic control modestly and reduces symptoms of diabetic neuropathy. NOW's combo includes 400 mg/day ALA at the standard 2-softgel protocol — inside the trial-active dose range.
Pooled analysis of 27 RCTs (n=2,569) at berberine 1,000-1,500 mg/day showing LDL −25%, triglycerides −35%, glucose improvements. NOW's 800 mg/day berberine sits below the trial window but partial response is documented.
Comprehensive review confirming ~1% oral bioavailability for berberine HCl. The softgel format used in NOW's combo doesn't fundamentally change bioavailability but may smooth peak luminal concentration, improving GI tolerance.
Berberine 500 mg 3×/day for 3 months in metabolic-syndrome subjects improved insulin sensitivity (Matsuda index), waist circumference, triglycerides, and systolic blood pressure. NOW's combo formula targets this metabolic-syndrome use case with complementary ALA insulin-mimetic action.
One free quiz · personalized AI Coach path · 4 missions this week. Build your character, build your life.
